NBP

NovaBridge Biosciences

Phase 1 AI-extracted

givastomig

HER2-negative metastatic gastric cancer

Resolved

7days ago

Phase 1 readout · ~ Jun 30, 2026 estimated

What's at stake Phase 1 trial results for givastomig in HER2-negative metastatic gastric cancer are due ~ Jun 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.

Primary source · SEC 6-K verified 13h ago

“Detailed Phase 1b expansion data are expected to be presented at a major medical conference in H2 2026”

Add to calendar Post on X Reddit

Provenance